- Home
- IMCR vs HMN Comparison
IMCR vs HMN Comparison
Compare IMCR & HMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- HMN
- Stock Information
- Founded
- IMCR 2008
- HMN 1945
- Country
- IMCR United Kingdom
- HMN United States
- Employees
- IMCR N/A
- HMN N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- HMN Property-Casualty Insurers
- Sector
- IMCR Health Care
- HMN Finance
- Exchange
- IMCR Nasdaq
- HMN Nasdaq
- Market Cap
- IMCR 1.4B
- HMN 1.7B
- IPO Year
- IMCR 2021
- HMN 1991
- Fundamental
- Price
- IMCR $30.16
- HMN $40.72
- Analyst Decision
- IMCR Buy
- HMN Hold
- Analyst Count
- IMCR 12
- HMN 3
- Target Price
- IMCR $60.90
- HMN $44.50
- AVG Volume (30 Days)
- IMCR 378.9K
- HMN 288.1K
- Earning Date
- IMCR 05-07-2025
- HMN 05-06-2025
- Dividend Yield
- IMCR N/A
- HMN 3.45%
- EPS Growth
- IMCR N/A
- HMN 127.61
- EPS
- IMCR N/A
- HMN 2.48
- Revenue
- IMCR $310,202,000.00
- HMN $1,595,200,000.00
- Revenue This Year
- IMCR $20.52
- HMN $9.77
- Revenue Next Year
- IMCR $8.57
- HMN $6.45
- P/E Ratio
- IMCR N/A
- HMN $16.41
- Revenue Growth
- IMCR 24.36
- HMN 6.92
- 52 Week Low
- IMCR $23.15
- HMN $31.81
- 52 Week High
- IMCR $62.74
- HMN $43.69
- Technical
- Relative Strength Index (RSI)
- IMCR 59.11
- HMN 49.42
- Support Level
- IMCR $27.55
- HMN $38.76
- Resistance Level
- IMCR $30.85
- HMN $40.99
- Average True Range (ATR)
- IMCR 1.95
- HMN 1.42
- MACD
- IMCR 0.44
- HMN -0.00
- Stochastic Oscillator
- IMCR 89.02
- HMN 55.21
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About HMN Horace Mann Educators Corporation
Horace Mann Educators Corp is a diversified insurance holding company that markets and underwrites personal lines of property and casualty insurance, retirement annuities, and life insurance. The company's property and casualty operations focus on automobile and homeowner insurance, while the retirement annuities are 403(b) tax-qualified products. Horace Mann Educators markets its products to kindergarten through 12th-grade teachers, administrators, and other employees of public schools and their families. The company uses several former teachers in its salesforce. Its segments include Property and Casualty, Supplemental & Group Benefits, Life & Retirement, and Corporate and Other.